These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 28822997)

  • 1. 18F-FDG PET/CT in solitary plasmacytoma: metabolic behavior and progression to multiple myeloma.
    Albano D; Bosio G; Treglia G; Giubbini R; Bertagna F
    Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):77-84. PubMed ID: 28822997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic role of pretreatment 18F-FDG PET/CT in primary brain lymphoma.
    Albano D; Bertoli M; Battistotti M; Rodella C; Statuto M; Giubbini R; Bertagna F
    Ann Nucl Med; 2018 Oct; 32(8):532-541. PubMed ID: 29982990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic role of baseline
    Albano D; Bosio G; Camoni L; Farina M; Re A; Tucci A; Giubbini R; Bertagna F
    Hematol Oncol; 2019 Feb; 37(1):39-46. PubMed ID: 30299563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma.
    Albano D; Bosio G; Pagani C; Re A; Tucci A; Giubbini R; Bertagna F
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):87-96. PubMed ID: 30276438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-[
    Albano D; Camoni L; Rodella C; Giubbini R; Bertagna F
    Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):e277-e283. PubMed ID: 33386279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic behavior and prognostic role of pretreatment 18F-FDG PET/CT in gist.
    Albano D; Bosio G; Tomasini D; Bonù M; Giubbini R; Bertagna F
    Asia Pac J Clin Oncol; 2020 Oct; 16(5):e207-e215. PubMed ID: 32762133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2-[
    Albano D; Calabrò A; Dondi F; Bertagna F
    Medicina (Kaunas); 2024 Jan; 60(2):. PubMed ID: 38399491
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in mantle cell lymphoma.
    Albano D; Bosio G; Bianchetti N; Pagani C; Re A; Tucci A; Giubbini R; Bertagna F
    Ann Nucl Med; 2019 Jul; 33(7):449-458. PubMed ID: 30929200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of initial FDG-PET/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myeloma.
    Fouquet G; Guidez S; Herbaux C; Van de Wyngaert Z; Bonnet S; Beauvais D; Demarquette H; Adib S; Hivert B; Wemeau M; Berthon C; Terriou L; Coiteux V; Macro M; Decaux O; Facon T; Huglo D; Leleu X
    Clin Cancer Res; 2014 Jun; 20(12):3254-60. PubMed ID: 24714772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [18F]FDG PET/CT and CA-125 in the evaluation of ovarian cancer relapse or persistence: is there any correlation?
    Dondi F; Albano D; Bertagna F; Giubbini R
    Nucl Med Rev Cent East Eur; 2022; 25(2):78-84. PubMed ID: 35848529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and Prognostic Role of 18F-FDG PET/CT in Pediatric Ewing Sarcoma.
    Albano D; Dondi F; Schumacher RF; D'Ippolito C; Porta F; Giubbini R; Bertagna F
    J Pediatr Hematol Oncol; 2020 Mar; 42(2):e79-e86. PubMed ID: 31135716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-FDG PET/CT in primary brain lymphoma.
    Albano D; Bosio G; Bertoli M; Giubbini R; Bertagna F
    J Neurooncol; 2018 Feb; 136(3):577-583. PubMed ID: 29147860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Impact of Pretreatment 2-[
    Albano D; Dondi F; Mazzoletti A; Bellini P; Giubbini R; Bertagna F
    Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34069203
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of baseline 2-[
    Albano D; Calabrò A; Dondi F; Bagnasco S; Tucci A; Bertagna F
    Hematol Oncol; 2024 Mar; 42(2):e3266. PubMed ID: 38444261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of 18F-fluorodeoxyglucose positron emission tomography before and after definitive radiation therapy in patients with apparently solitary plasmacytoma.
    Kim PJ; Hicks RJ; Wirth A; Ryan G; Seymour JF; Prince HM; Mac Manus MP
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):740-6. PubMed ID: 19038505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG PET/CT in gastric MALT lymphoma: a bicentric experience.
    Albano D; Bertoli M; Ferro P; Fallanca F; Gianolli L; Picchio M; Giubbini R; Bertagna F
    Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):589-597. PubMed ID: 27619357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone.
    Nanni C; Rubello D; Zamagni E; Castellucci P; Ambrosini V; Montini G; Cavo M; Lodi F; Pettinato C; Grassetto G; Franchi R; Gross MD; Fanti S
    In Vivo; 2008; 22(4):513-7. PubMed ID: 18712181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiation of soft tissue and bone sarcomas from benign lesions utilizing
    Chen B; Feng H; Xie J; Li C; Zhang Y; Wang S
    BMC Med Imaging; 2020 Jul; 20(1):85. PubMed ID: 32711449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of 18F-FDG PET/CT in staging and restaging primary bone lymphoma.
    Liu Y
    Nucl Med Commun; 2017 Apr; 38(4):319-324. PubMed ID: 28225435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor markers and
    Dondi F; Albano D; Bertagna F; Giubbini R
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2021; 40(5):287-292. PubMed ID: 34425969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.